Graeme R. Robb

机构：AstraZeneca (Singapore), AstraZeneca (Switzerland) · ORCID：0000-0002-4531-4375

发表论文 71 篇 · 总被引 2146 次 · h-index 25

代表论文

• Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6 (2018 · ACS Chemical Biology · 被引 141)
• Potent and selective bivalent inhibitors of BET bromodomains (2016 · Nature Chemical Biology · 被引 139)
• The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one) (2018 · Journal of Medicinal Chemistry · 被引 123)
• Structure-Based Design and Pharmacokinetic Optimization of Covalent Allosteric Inhibitors of the Mutant GTPase KRASG12C (2020 · Journal of Medicinal Chemistry · 被引 87)
• Learning Medicinal Chemistry Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) Rules from Cross-Company Matched Molecular Pairs Analysis (MMPA) (2017 · Journal of Medicinal Chemistry · 被引 84)
• Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors (2017 · Journal of Medicinal Chemistry · 被引 78)